Skip to main content
. 2012 Nov 17;4(1):18–28. doi: 10.18632/oncotarget.725

Figure 6. Pargyline treatment increased the global H3K4 methylation and H3K9 acetylation marks and reduced the H3K9 methylation in xenograft tumors.

Figure 6

(A) IHC analysis of H3K4-me2, H3K9-me2 and H3K9-Ac marks was done on xenograft tumors that were treated with vehicle or pargyline (Left panel). Quantitation was done as described in the methods section. All data presented are the mean ± SEM. *, p< 0.05. (Right panel). (B) Total RNA was isolated from control or pargyline-treated tumors and subjected to RT-qPCR using the primers specific for p21 and PUMA. All data presented are the mean ± SEM. *, p< 0.05. (C) U87 cells were treated with pargyline or NCL-1 and ChIP analysis was performed using H3K4-me2 and H3K9-me2 antibodies and the status of epigenetic modification was analyzed using real-time PCR with p21 promoter-specific primers.